Cardio-oncology Related to Heart Failure, An Issue of Heart Failure Clinics (Volume 7-3)

by Daniel J. Lenihan, Douglas B. Sawyer

As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects.  Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis.  This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.

168 pages, Hardcover

First published July 28, 2011

About the author

Also publishes under Daniel Lenihan